Skip to main content

Table 1 Clinical, Electrocardiographic, and Doppler Echocardiographic Data of the proband and her family members. Approximate normal ranges of echocardiographic data according to published sources are shown in brackets

From: A case report of recessive restrictive cardiomyopathy caused by a novel mutation in cardiac troponin I (TNNI3)

Member of the family

TNNI3 genetic status

Current age/sex

Age at symptom onset-examination

Height (m)/ BSA (m2)

ECG, Arrhythmia

LVEDD (mm)

IVSd (mm)

PWd (mm)

LVESD (mm)

LVEF %

LAVi (ml/m2)

RAVi (ml/m2)

E (cm/s)

A (cm/s)

E/A

DT (ms)

Accompanying disease/habits (therapy)

II1

Hom

49 M

42

1.75/2.01

SR, incomplete RBBB, LV strain

47 [42–58]

12 [6–10]

10 [6–10]

30 [25–40]

60 [52–72]

53.7 [16–34]

38.8 [11–39]

54 [40–104]

71 [32–92]

0.77 [0.60–1.84]

190 [81–293]

HCM, NYHA II, presyncope, Dyslipidemia, smoker (acetylsalicylic acid, rosuvastatin)

Proband

II2

Hom

52F

41

1.60/1.49

AF, LVH, LV strain

45 [38–52]

7 [6–9]

7 [6–9]

31 [22–35]

50 [54–74]

127.5 [16–34]

100.7 [9–33]

60 [43–111]

na (AF)

na (AF)

110 [109–268]

RCM, NYHA III-IV (acenocumarol, metoprolol tartate, furosemide, amiloride)

II3

Hom

52F

45

1.60/1.59

SR, incomplete RBBB, LV strain

44 [38–52]

8 [6–9]

8 [6–9]

30 [22–35]

55 [54–74]

94.3 [16–34]

47.2 [9–33]

65 [43–111]

24 [35–91]

2.71 [0.4–2.12]

104 [109–268]

RCM, NYHA II (furosemide)

II4

Het

55F

 

1.65/1.79

SR

42 [38–52]

7 [6–9]

7 [6–9]

26 [22–35]

55 [54–74]

33.5 [16–34]

27.9 [9–33]

63 [43–111]

75 [35–91]

0.87 [0.4–2.12]

300 [109–268]

Asymptomatic

I1

Het

75 M

 

1.70/1.94

SR

46 [42–58]

10 [6–10]

10 [6–10]

27 [25–40]

65 [52–72]

23.2 [16–34]

23.7 [11–39]

60 [37–97]

75 [41–105]

0.80 [0.42–1.50]

280 [78–357]

Asymptomatic

Dyslipidemia (rosuvastatin)

I2

Het

72F

 

1.70/2.00

SR

41 [38–52]

10 [6–9]

9 [6–9]

26 [22–35]

55 [54–74]

35 [16–34]

27.9 [9–33]

50 [38–106]

75 [44–108]

0.67 [0.37–1.61]

310 [90–313]

Asymptomatic

Increased apical trabeculations, AH, Dyslipidemia (olmesartan, rosuvastatin, acetylsalicylic acid)

III2

Het

13F

 

1.61/1.45

SR

48 [38–52]

7 [6–10]

6 [6–10]

27 [22–35]

60 [54–74]

33.0 [18–34]

14.9a [9.5–19.3]

100 [50–118]

70 [27–75]

1.43 [0.68–2.76]

190 [97–257]

Asymptomatic

III3

Het

21 M

 

1.78/1.97

SR

50 [42–58]

8 [6–10]

9 [6–10]

34 [25–40]

55 [52–72]

25.4 [16–34]

22.3 [11–39]

80 [51–107]

45 [24–76]

1.78 [0.65–2.73]

195 [87–273]

Asymptomatic

  1. a for pediatric patient III2 Right Atrial Area is documented instead of RAVi
  2. A: maximal velocity of the late atrial component of transmitral blood flow, AF: Atrial Fibrillation, AH: Arterial Hypertension, BSA: Body Surface Area calculated with Mosteller formula, DT: Deceleration Timeof early transmitral flow (time from maximal velocity to zero), E: maximal early transmitral blood flow velocity, ECG: ElectroCardioGram, HCM: Hypertrophic Cardiomyopathy, Het: heterozygous, Hom: homozygous, IVSd: Interventricular Septum Diameter, LAVi: Left Atrial Volume indexed to BSA, LV: Left Ventricle, LVEDD: Left Ventricular End Diastolic Diameter, LVEF: LV Ejection Fraction, LVESD: Left Ventricular End Systolic Diameter, LVH: Left Ventricular Hypertrophy, na: not applicable, NYHA: New York Heart Association class, PWd: Posterior Wall Diameter, RAVi: Right Atrial Volume indexed to BSA, RBBB: Right Bundle Branch Block, RCM: Restrictive Cardiomyopathy, SR: Sinus Rhythm
  3. Abnormal values are shown in bold letters